Recombinant NDV Vectored Vaccine for SARS-CoV-2

BIOLOGICAL2 trials

Sponsors

Laboratorio Avi-Mex, S.A. de C.V.

Conditions

SARS CoV 2 InfectionSARS-CoV-2 Infection

Phase 1

Study of a Live rNDV Based Vaccine Against COVID-19

CompletedNCT04871737

Laboratorio Avi-Mex, S.A. de C.V.SARS-CoV-2 Infection

Start: 2021-05-20End: 2022-09-30Updated: 2023-07-25

Phase 2

Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence

CompletedNCT05205746

Laboratorio Avi-Mex, S.A. de C.V.SARS CoV 2 Infection

Start: 2021-11-23End: 2023-07-24Updated: 2025-10-02

Related Papers

Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico.

2023-05-1032 citations

Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid

Journal of Visualized Experiments2022-05-253 citations

Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid

Journal of Visualized Experiments2022-05-251 citations